BTER Admit Card 2017

The long-term trend of the EPS is an important number as it indicates the present value of Laureate Education. The EPS growth rate, as it is usually called, is typically displayed as a percentage, which is 12.00%. Growth in EPS is an important measure of administration performance because it shows how much money Laureate Education is making for it’s investors or shareholders.

Laureate Education trades as part of the consumer defensive sector and trades as part of the education industry. The company CEO is Eilif Serck-Hanssen. Laureate Education Inc is an international community of universities. The company provides higher education programs and services to students through an international network of licensed universities and higher education institutions.

Previous Intraday Performance:

The LAUR shares had a previous change of -2.49% which opened at 15.41 and closed at 15.07. It moved to an intraday high of 15.53 and a low of 14.65.

SeekingAlpha:  Laureate Education cleared in DOJ probe

Historical Performance:

Over the last five trading days, LAUR shares returned 3.65% and in the past 30 trading days it returned -1.25%. Over three months, it changed -5.87%. In one year it has changed 23.32% and within that year its 52-week high was 17.15 and its 52-week low was 11.98. LAUR stock is 25.79% above its 52 Week Low.

Our calculations result in a 200 day moving average of 14.85 and a 50 day moving average of 15.11. Right now, LAUR stock is trading 1.46% above its 200 day moving average and may be a good opportunity to buy.

SeekingAlpha:  Laureate Education cleared in DOJ probe


The company has a market cap of $3.4b with 224.0m shares outstanding and a float of 223.5m shares. Trading volume was 1,088,956 shares and has experienced an average volume of 1,001,575 shares. Our calculation, using the current average volume and close price, leads me to believe that the liquidity is bad, highly speculative and an investor may want to avoid this stock.


The last annual reported EPS for Laureate Education was -1.22 which ended on 31st of December 2017. Based on 5 analyst estimates, the consensus EPS for the next quarter is -0.22. The trailing twelve month EPS is 0.46, which comes to a trailing twelve month PE of 32.76.

Below was the last reported quarterly earnings per share:
09-30-2018:  -0.18
06-30-2018:  1.00
03-31-2018:  -0.84
12-31-2017:  0.48

Base on our calculations, the intrinsic value per share is 11.84, which means it might overvalued by -27.33%

Indicators Also to Watch:

Based on the latest filings, there is 50.30% of institutional ownership. Short-interest was 0, which was 0.00% of shares outstanding. The short-interest ratio or days-to-cover ratio was 0.00.

I calculated the beta to be 0.82

SeekingAlpha:  Insmed misses by $0.08

Fundamental Numbers:

Based on last reported financials, the company’s return on equity is 22.77%, return on assets is 5.45%, profit margin is 13.59%, price-to-sales is 0.83 and price-to-book is 1.75.

Company Score Card:

Results are out of six:
 0  : Growth Expectations Result
 0  : Financial Safety Result
 2  : Past Performance Result
 1  : Valuation Result
 0  : Dividend Safety Result
 0  : Overall Result

Related Tags: , , ,

Jake McWilliams
I am an independent trader, analyst and algorithmic trading expert, having worked both for the sell side (brokerage) and the buy side (fund administration). I have been trading professionally for about 20 years. I trade stocks and forex and I play both long and short positions in underlying asset or through options. I have experience with discretionary and fully automated systems (Metatrader and Quantshare).


Please enter your comment!
Please enter your name here